Successful exit: Miltenyi Biotec acquires biosensor company lino Biotech
lino Biotech, a biosensor company and the world’s only provider of Focal Molography®, announced it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023.
Symbolic image
Unsplash/pixabay.com
Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy manufacturing, and testing for off-target responses in living cells to support drug discovery.
Headquartered in Bergisch Gladbach, Miltenyi Biotec has been a global provider of products and services for biomedical research and cellular therapy for more than 30 years.
Under the terms of the transaction, Miltenyi Biotec will acquire 100% of the shares from the investors including Roche Venture Fund and High-Tech Gründerfonds (HTGF). The specific terms of the transaction were not disclosed. Brown Gibbons Lang & Company (BGL), acted as the exclusive financial advisor to lino Biotech.
"lino´s innovative biosensor platform and Miltenyi’s cell and gene therapy approaches offer exciting synergies to lower the cost and establish a new standard for potency assays", Dr. Mirko Stange, CEO of lino Biotech.
"The HTGF is very pleased that lino Biotech AG with its technically demanding project, which the HTGF III has advanced together with the founding team and Roche Venture, find its application within the German Mittelstand", Dr. Martin Pfister, Principal at High-Tech Gründerfonds.
Other news from the department business & finance
These products might interest you
Octet R2 / Octet R4 / Octet R8 by Sartorius
Full power on 2, 4 or 8 channels: Label-free and GxP-compliant analysis of molecular interactions
Innovative label-free real-time protein quantification, binding kinetics and rapid screenings
Octet RH16 and RH96 by Sartorius
Efficient protein analysis for process optimisation and manufacturing control in high-throughput
Label-free protein quantification and characterization of protein-protein interactions
Octet SF3 by Sartorius
Surface Plasmon Resonance (SPR) using Single Dynamic Injections for Kinetics and Affinities
Curvature is Key - Adding a ‘Third Dimension’ to the Binding Curve
Most read news
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Last viewed contents
Developing countries lead the way in the global adoption of biotech crops
Dental_implant
